ストックスクリーナーアプリを入手
4.59
2.23%
0.10
プレマーケット:
4.67
0.08
+1.74%
Emergent Biosolutions Inc (EBS) 最新ニュース
Emergent Biosolutions Inc. (NYSE:EBS) Given Average Rating of "Hold" by Analysts - MarketBeat
Q2 2025 Emergent BioSolutions Inc Earnings Call Transcript - GuruFocus
Q4 2025 Emergent BioSolutions Inc Earnings Call Transcript - GuruFocus
Q1 2026 Emergent BioSolutions Inc Earnings Call Transcript - GuruFocus
Emergent BioSolutions Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
American Century group reports 5.4% Emergent BioSolutions (EBS) ownership on Schedule 13G - Stock Titan
Emergent Biosolutions (EBS) Earnings Date and Reports 2026 $EBS - MarketBeat
Levi & Korsinsky Notifies Investors of Pending - globenewswire.com
Emergent Biosolutions (NYSE:EBS) Rating Increased to Hold at Zacks Research - MarketBeat
Emergent BioSolutions (EBS) Q2 2026 Earnings Call Transcript - AOL.com
EBS Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Emergent BioSolutions (EBS) - Business Wire
Emergent BioSolutions (EBS) EVP Stephanie Duatschek details stock and option holdings - Stock Titan
Trade Desk, Papa John's, Emergent BioSolutions Hit 52-Week Lows as Weak Results Trigger Analyst Downgrades - finance.biggo.com
EBS SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Emergent BioSolutions - PR Newswire
EMERGENT BIOSOLUTIONS INC. : H.C. WAINWRIGHT CUTS TARGET PRICE TO $10 FROM $12 - webull.com
Why Did TTD, PZZA, EBS Stocks Plummet To 52 Week Lows? - Stocktwits
Emergent BioSolutions cuts FY2026 revenue forec... - Pluang
Emergent BioSolutions Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Emergent BioSolutions (EBS) - PR Newswire
H.C. Wainwright Maintains Emergent BioSolutions(EBS.US) With Buy Rating, Cuts Target Price to $10 - Moomoo
H.C. Wainwright cuts Emergent BioSolutions stock price target on revenue outlook - Investing.com Nigeria
Emergent Biosolutions (NYSE:EBS) Given New $10.00 Price Target at HC Wainwright - MarketBeat
EBS Maintained by HC Wainwright & Co. -- Price Target Lowered to $10 - GuruFocus
Emergent BioSolutions Inc (EBS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Emergent BioSolutions (EBS) Stock Sinks As NARCAN Impairment Deepens Losses - Sahm
Emergent BioSolutions Inc (EBS) Stock News Today - tradingkey.com
Emergent Biosolutions Q2 Earnings Call Highlights - MarketBeat
Watch Out on Emergent BioSolutions Inc.: Strong Operational Recovery Tempered by Commercial Headwinds and Strategic Reset - Kalkine
Despite Hitting US$5.31, Emergent BioSolutions Insiders Still Sold Too Soon - 富途牛牛
Pacer Advisors Inc. Purchases Shares of 416,191 Emergent Biosolutions Inc. $EBS - MarketBeat
Emergent BioSolutions Inc. (EBS): Investor Outlook Reveals 125.99% Potential Upside - DirectorsTalk Interviews
Dimensional Fund Advisors LP Has $22.88 Million Position in Emergent Biosolutions Inc. $EBS - MarketBeat
Emergent BioSolutions Shares Plunge After 2026 Guidance Cut, Restructuring - Moomoo
Emergent BioSolutions Announces Restructuring Amid Turnaround Efforts - The Globe and Mail
Emergent BioSolutions laying off dozens, shedding real estate as Narcan competition strains profits - The Business Journals
Emergent BioSolutions | 10-Q: Q2 2026 Earnings Report - Moomoo
Emergent Bio stock slips despite Q2 beat (EBS:NYSE) - Seeking Alpha
Emergent BioSolutions Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Emergent BioSolutions Inc. 2026: Revenue $234.3M, EPS ($3.49) — 10-Q Summary - TradingView
Emergent BioSolutions (NYSE: EBS) posts Q2 loss, plans cost-cutting - Stock Titan
Emergent Q2 2026 slides: strong quarter, but guidance cut sparks selloff - Investing.com
Emergent Biosolutions (NYSE:EBS) Announces Quarterly Earnings Results - MarketBeat
Earnings call transcript: Emergent BioSolutions Q2 2026 revenue tops guidance - Investing.com
Emergent BioSolutions Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Is Emergent BioSolutions Inc (EBS) Overvalued After Q2 Earnings - GuruFocus
Emergent Q2 2026 slides: MCM strength offset by naloxone pressure - Investing.com
EBS: Strong Q2 driven by MCM, but naloxone competition prompts lower guidance and restructuring - TradingView
Emergent BioSolutions Inc. 2026 Q2ResultsEarnings Call Presentation (NYSE:EBS) 2026-08-05 - Seeking Alpha
Emergent Q2 2026 earnings: MCM growth contrasts with NARCAN impairment - TradingKey
Q2 2026 Emergent BioSolutions Inc Earnings Call Transcript - GuruFocus
Emergent BioSolutions Reports Second Quarter 2026 Financial Results - The Manila Times
Emergent Biosolutions: Q2 Earnings Snapshot - Yahoo Finance
Emergent BioSolutions swings to Q2 loss on impairment charge; to cut jobs - TradingView
Emergent BioSolutions Commits to Cross-Sector Collaboration Against Biological Threats in an Evolving Global Security Environment - marketscreener.com
Emergent BioSolutions Inc. Reports Impairment of Long-Lived Assets for the Second Quarter Ended June 30, 2026 - marketscreener.com
Emergent Biosolutions Inc. Announces Management Changes - marketscreener.com
Emergent BioSolutions Inc expected to post earnings of 11 cents a shareEarnings Preview - TradingView
Emergent BioSolutions Inc. (EBS) Stock Analysis: A 65% Upside Potential Despite Challenges - DirectorsTalk Interviews
Vanguard Capital Management (EBS) discloses 4.92% Emergent BioSolutions ownership - Stock Titan
Emergent Biosolutions (EBS) Projected to Post Earnings on Wednesday - MarketBeat
BlackRock (NYSE: BLK) reports 9.0% ownership of Emergent BioSolutions (EBS) stock - Stock Titan
EBS|Emergent BioSolutions Inc|Price:7.325|Chg%:+0.065 - TradingKey
Emergent BioSolutions Inc (EBS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Emergent BioSolutions Inc (EBS) Cash Flow - TradingKey
Emergent BioSolutions Inc (EBS) Income Statement - TradingKey
EBS|Emergent BioSolutions Inc|Price:7.260| - TradingKey
0.79%
5.15%
大文字化:
|
ボリューム (24 時間):